中國寶安(000009.SZ):子公司貝特瑞擬投資不超26.18億元在摩洛哥建設年產6萬噸鋰電池負極材料一體化項目
格隆匯8月13日丨中國寶安(000009.SZ)公佈,公司下屬子公司貝特瑞新材料集團股份有限公司(以下簡稱"貝特瑞")為實施鋰電池負極材料海外戰略佈局,擬通過其全資子公司貝特瑞地中海負極新材料科技有限公司在摩洛哥投資建設年產6萬噸鋰電池負極材料一體化項目,項目預計總投資額不超過人民幣26.18億元。
在新能源汽車行業持續發展的背景下,貝特瑞為了更好地服務客户、滿足市場需求及拓展海外市場份額,提升其在負極材料領域的綜合競爭力,擬在摩洛哥投資建設負極材料產能。若本項目順利建成並全部達產,將新增年產6萬噸負極材料產能,預計對公司產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.